ESPR Key Statistics, Chart & Performance
The current stock price of ESPR is 3.165 USD. In the past month the price decreased by -14.55%. In the past year, price increased by 46.15%.
ESPR Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ESPR. When comparing the yearly performance of all stocks, ESPR is one of the better performing stocks in the market, outperforming 88.03% of all stocks.
ESPR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ESPR. ESPR has a bad profitability rating. Also its financial health evaluation is rather negative.
ESPR Financial Highlights
Over the last trailing twelve months ESPR reported a non-GAAP Earnings per Share(EPS) of -0.5. The EPS increased by 21.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.07% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ESPR Forecast & Estimates
14 analysts have analysed ESPR and the average price target is 6.59 USD. This implies a price increase of 108.35% is expected in the next year compared to the current price of 3.165.
For the next year, analysts expect an EPS growth of 68.18% and a revenue growth 26.51% for ESPR
ESPR Ownership
ESPR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.96 | 976.29B | ||
| JNJ | JOHNSON & JOHNSON | 21.1 | 527.64B | ||
| MRK | MERCK & CO. INC. | 12.58 | 275.08B | ||
| PFE | PFIZER INC | 7.99 | 145.33B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.54 | 114.09B | ||
| ZTS | ZOETIS INC | 19.63 | 54.84B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.71 | 23.05B | ||
| VTRS | VIATRIS INC | 5.51 | 14.77B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.11 | 11.98B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.85B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.31B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.22B |
Related stock screener links
About ESPR
Company Profile
Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The company is headquartered in Ann Arbor, Michigan and currently employs 304 full-time employees. The company went IPO on 2013-06-24. The firm is focused on developing and commercializing oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (CVD) and are struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines to lower the risk of myocardial infarction and coronary revascularization in adults with primary hyperlipidemia. Its NEXLETOL is an ATP Citrate Lyase (ACLY), inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.
Company Info
ESPERION THERAPEUTICS INC
3891 Ranchero Drive, Suite 150, Suite 300
Ann Arbor MICHIGAN 48108 US
CEO: Tim M. Mayleben
Employees: 304
Phone: 17348873903
ESPERION THERAPEUTICS INC / ESPR FAQ
What does ESPERION THERAPEUTICS INC do?
Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The company is headquartered in Ann Arbor, Michigan and currently employs 304 full-time employees. The company went IPO on 2013-06-24. The firm is focused on developing and commercializing oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (CVD) and are struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines to lower the risk of myocardial infarction and coronary revascularization in adults with primary hyperlipidemia. Its NEXLETOL is an ATP Citrate Lyase (ACLY), inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.
What is the current price of ESPR stock?
The current stock price of ESPR is 3.165 USD. The price decreased by -2.01% in the last trading session.
What is the dividend status of ESPERION THERAPEUTICS INC?
ESPR does not pay a dividend.
What is the ChartMill technical and fundamental rating of ESPR stock?
ESPR has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists ESPR stock?
ESPR stock is listed on the Nasdaq exchange.
Can you provide the sector and industry classification for ESPERION THERAPEUTICS INC?
ESPERION THERAPEUTICS INC (ESPR) operates in the Health Care sector and the Pharmaceuticals industry.